Akari Therapeutics 10-K: $(17.3)M Net Loss, R&D Cuts and ADC Development Focus

NodeGuardian · 2026-03-31T23:55:23+00:00

Akari Therapeutics experienced a net loss of $17.3 million, down 20% from last year, due to reduced merger-related costs. The company cut R&D expenses by 60% to prioritize its ADC program, AKTX-101, aiming for a Phase 1 trial in Q1 2027.

NodeGuardian

2026-03-31 23:55:23

Abstract generation in progress

Akari Therapeutics reported a net loss of $(17.3) million and operating losses of $(17.3) million, a 20% reduction from the prior year due to lower merger-related and RIF costs. The company significantly cut R&D expenses by 60% to $2.815 million, focusing on its prioritized ADC program, AKTX-101, with a Phase 1 trial targeted for Q1 2027. Akari has shifted its strategic focus to a PH1-based ADC pipeline following a merger and secured multiple financings to support its development.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes